Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- MHLW Study Group Decides on Next 5-Year Plan for Activation of Clinical Research
March 27, 2012
- Council for Improvement of the Distribution of Ethical Drugs Agrees to Establish Working Team, Focus on Spreading “Mutual Understanding”
March 27, 2012
- “No Serious ADR” Found in MHLW’s Fixed-Point Observation for Byetta
March 27, 2012
- Council Approves 80 Development Requests from 2nd Round
March 27, 2012
- PMDA to Improve Review, Safety Standards to Become World-Class Regulatory Authority: Chief Executive Kondo
March 26, 2012
- Notification Calls for Revision of Package Inserts for Diabetes, MS Treatments
March 23, 2012
- Kawasaki’s Tonomachi District to Invite NIHS, Set to Become International Basis for R&D
March 23, 2012
- Eliminating Drug Lag Will Require Measures to Reduce “Application Lag”: Mr Akagawa of PFSB
March 22, 2012
- Council Meeting Considers Working Team to Explore Directions for Drug Distribution Improvement
March 21, 2012
- Pharmaceutical Industry Should be Fostered as “Core Industry Taxed Not Punished”: Mr Sengoku of DPJ
March 21, 2012
- CSIMC to Accelerate Discussions on Long-Listed Drugs, Cost-Benefit Assessments: Dr Suzuki of HIB
March 21, 2012
- Health Insurance Claims Services Releases 37 Additional Cases Based on “1980 Notice”
March 19, 2012
- Generics Not Listed in All Specifications to Be Delisted from April 1 with Some Exceptions
March 19, 2012
- MHLW Submits Application for Membership in PIC/S on March 9
March 19, 2012
- PMDA to Abolish Current Rule on Re-Employment of Its Former Employees
March 16, 2012
- Integration of Advanced Healthcare Service Systems “Not Related” to Compassionate Use System: Korosho
March 16, 2012
- Bill to Amend PAL Unlikely to Be Submitted in Current Diet Session Due to Time Constraints: Health Minister Komiyama
March 15, 2012
- Korosho Begins Discussions Toward Integrating Senshin-iryo, Kohdo-iryo Systems
March 15, 2012
- Dr Sakurai of PMDA Stresses Need for Japan’s Participation in PIC/S to Create Global Inspection System
March 14, 2012
- Dissolution of Gliclazide Tablets Attributed to Large Particle Size: Generic Drug Quality Study Group
March 13, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…